We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+16.48%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$281M
AUM Growth
–
Cap. Flow
+$266M
Cap. Flow %
94.74%
Top 10 Hldgs %
79.69%
Holding
19
New
19
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$27.9M
2
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$26.8M
3
UTHR icon
United Therapeutics
UTHR
+$26.3M
4
NPSP
NPS PHARMACEUTICALS INC
NPSP
+$25.5M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$23.6M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 39.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLXP
1
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$31M 11.01%
+467,943
New +$26.8M
NPSP
2
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$27.8M 9.88%
+1,839,263
New +$25.5M
UTHR icon
3
United Therapeutics
UTHR
$26.3B
$26.9M 9.55%
+408,166
New +$26.3M
MDCO
4
DELISTED
Medicines Co
MDCO
$25.7M 9.13%
+834,798
New +$27.9M
ARIA
5
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$23.3M 8.28%
+1,331,100
New +$23.6M
FURX
6
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$22.2M 7.88%
+650,608
New +$22.8M
JAZZ icon
7
Jazz Pharmaceuticals
JAZZ
$15.9B
$21.5M 7.65%
+312,858
New +$19.1M
AMAG
8
DELISTED
AMAG Pharmaceuticals
AMAG
$16.4M 5.83%
+737,186
New +$16.2M
AFFX
9
DELISTED
Affymetrix Inc
AFFX
$15.3M 5.43%
+3,436,940
New +$13.1M
EBS icon
10
Emergent Biosolutions
EBS
$375M
$14.2M 5.04%
+983,669
New +$14.2M
CSII
11
DELISTED
Cardiovascular Systems, Inc.
CSII
$13.2M 4.7%
+622,901
New +$12.1M
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$312M
$11.6M 4.11%
+1,429,798
New +$9.63M
QCOR
13
DELISTED
QUESTCOR PHARMA INC
QCOR
$9.09M 3.23%
+200,000
New +$7.09M
TARO
14
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$7.5M 2.67%
+134,199
New +$7.93M
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
$5.53M 1.97%
+82,500
New +$3.71M
CHDX
16
DELISTED
CHINDEX INTL INC
CHDX
$5.43M 1.93%
+334,615
New +$4.93M
LPDX
17
DELISTED
LIPOSCIENCE INC COM
LPDX
$2.95M 1.05%
+422,263
New +$3.23M
SCMP
18
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$1.18M 0.42%
+179,988
New +$1.43M
AMRN
19
Amarin Corp
AMRN
$284M
$673K 0.24%
+5,800
New +$800K

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Consonance Capital Management, which disclosed 19 positions worth $281M. Its ten largest holdings account for 80% of the portfolio.

Its largest position is Medicines Co: 834,798 shares worth $25.7M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets.

  • Consonance Capital Management's largest Q2 2013 buy was Medicines Co: 834,798 shares worth $25.7M.
  • Consonance Capital Management's ten largest holdings make up 80% of its $281M portfolio in Q2 2013.
  • Consonance Capital Management disclosed 19 positions in Q2 2013, its first 13F filing on record.

Based on Consonance Capital Management's 13F filing for Q2 2013, filed 12 Aug 2013.